Avalo Therapeutics (AVTX) Earnings Date, Estimates & Call Transcripts $12.41 -1.07 (-7.94%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Avalo Therapeutics Latest Earnings SummaryUpcoming Q3 Earnings DateApr. 4EstimatedActual EPS (Aug. 12) -$14.07 Missed By -$7.37 Consensus EPS (Aug. 12) -$6.70 Avalo Therapeutics announced Q2 2024 earnings on August 12, 2024, reporting an EPS of -$14.07, which missed the consensus estimate of -$6.70 by $7.37. With a trailing EPS of $0.00, Avalo Therapeutics' earnings are expected to grow next year, from ($19.07) to ($4.70) per share. AVTX Upcoming EarningsAvalo Therapeutics' next earnings date is estimated for Friday, April 4, 2025, based off prior year's reporting schedules. Get Avalo Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalo Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAVTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AVTX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Avalo Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ3 20241-$0.93-$0.93-$0.93Q4 20241-$0.98-$0.98-$0.98 Avalo Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 4/4/2025(Estimated)------- 8/12/2024Q2 2024-$6.70-$14.07 -$7.37-$14.07--5/13/2024Q1 2024-$1.18-$5.98 -$4.80$129.04--11/9/2023Q3 2023-$264.00-$26.40+$237.60-$0.11$1.00M$0.24M8/3/2023Q2 2023-$216.00-$141.60+$74.40-$0.59$1.00M$0.64M5/4/2023Q1 2023-$232.80-$204.00+$28.80-$0.85$1.00M$0.48M3/29/2023Q4 2022-$124.80-$249.60 -$124.80-$1.04$5.20M$0.90M Get the Latest News and Ratings for AVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Avalo Therapeutics Earnings - Frequently Asked Questions When is Avalo Therapeutics's earnings date? Avalo Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, April 4th, 2025 based off last year's report dates. Learn more on AVTX's earnings history. Did Avalo Therapeutics beat their earnings estimates last quarter? In the previous quarter, Avalo Therapeutics (NASDAQ:AVTX) missed the analysts' consensus estimate of ($6.70) by $7.37 with a reported earnings per share (EPS) of ($14.07). Learn more on analysts' earnings estimate vs. AVTX's actual earnings. How much revenue does Avalo Therapeutics generate each year? Avalo Therapeutics (NASDAQ:AVTX) has a recorded annual revenue of $1.92 million. How much profit does Avalo Therapeutics generate each year? Avalo Therapeutics (NASDAQ:AVTX) has a recorded net income of -$31.54 million. AVTX has generated $0.00 earnings per share over the last four quarters. What is Avalo Therapeutics's EPS forecast for next year? Avalo Therapeutics's earnings are expected to grow from ($19.07) per share to ($4.70) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Sol-Gel Technologies Earnings Results Vincerx Pharma Earnings Results GlycoMimetics Earnings Results OS Therapies Earnings Results SCYNEXIS Earnings Results OncoCyte Earnings Results Immix Biopharma Earnings Results Imunon Earnings Results Rallybio Earnings Results Unicycive Therapeutics Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for Investors Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. This page (NASDAQ:AVTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
